{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-017157","form_type":"8-K/A","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.175178+00:00","generated_at":"2026-06-05T13:08:33.360868+00:00","sec_items":["1.01","2.01","5.06","9.01","5.02","3.02","5.01","5.03"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CERo Therapeutics completes reverse merger with SPAC Phoenix Biotech on Feb 14, 2024, raising $9.98M in PIPE","bullets":["Business combination closed; PBAX renamed to CERo Therapeutics Holdings, Inc.; common stock and warrants trade on Nasdaq as CERO and CEROW.","PIPE financing raised ~$9.98M via sale of Series A convertible preferred, common warrants, and preferred warrants to accredited investors.","Equity line of credit with lead investor allows sale of up to ~2.98M shares over 36 months at 90% of VWAP; 119,050 commitment shares issued.","Consideration included 8.46M shares to CERo stockholders (including 3.08M earnout shares tied to price/milestones) and 1.63M shares to vendors in lieu of $8.54M cash.","Sponsor forfeited 875K shares at closing; 1.76M shares subject to 180-day lock-up; Promissory Note of $1.55M extinguished."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-017157","json":"https://secwatch.observer/filing/0001213900-24-017157.json","markdown":"https://secwatch.observer/filing/0001213900-24-017157.md","text":"https://secwatch.observer/filing/0001213900-24-017157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/ea193847-8ka1_cerothera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:08:33.360868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f546cd728","claim":"Ms. Loewy resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3f82cfef7e","claim":"Mr. Corey was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5cf03dd7ef","claim":"Robyn Rapaport was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8963e8121f","claim":"Mr. Corey was appointed as Chief Technical Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Corey was appointed as the Company’s Chief Technical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Technical Officer"}],"fact_type":"executive_change"},{"claim_id":"a07d623c2f","claim":"Mr. Byrnes was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b30f855f3d","claim":"Ms. Kosacz resigned as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Ms. Kosacz and Ms. Loewy resigned from the board of directors of PBAX and any committees thereof","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c29dca26da","claim":"Mr. Atwood was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dfd1b318ce","claim":"Mr. Carter was appointed as Chief Financial Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Carter was appointed as the Company’s Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e6a337c65f","claim":"Lindsey Rolfe was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"electing each of Lindsey Rolfe and Robyn Rapaport to serve as a director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ea011176d0","claim":"Mr. Atwood was appointed as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Atwood was appointed as the Company’s Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"eb136a2c6b","claim":"Ms. LaPorte was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f3f9371c80","claim":"Mr. Ehrlich was appointed as Director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Mr. Byrnes, Mr. Atwood, Ms. LaPorte, Mr. Corey and Mr. Ehrlich were appointed as directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"290df82591dfa460c2f0e3dd19d263dcdf7f75e1","claim":"CERO THERAPEUTICS HOLDINGS, INC. underwent a change of control involving Phoenix Biotech Acquisition Corp. (PBAX) for Issuance of 8,457,653 shares of Common Stock (including 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants) (closed 2024-02-14).","evidence_excerpt":"the earlier of such forfeiture or the expiration of the earnout period. As consideration for the Business Combination, the Company issued to CERo stockholders an aggregate of 8,457,653 shares of Common Stock, including 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants. The foregoing description of the Business","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.95,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Phoenix Biotech Acquisition Corp. (PBAX)"},{"label":"Consideration","value":"Issuance of 8,457,653 shares of Common Stock (including 3,075,000 Earnout Shares and 382,653 shares issuable upon exercise of rollover options or warrants)"},{"label":"Closing","value":"2024-02-14"}],"fact_type":"ma_transaction"},{"claim_id":"4a011a8172898389f528bc7ecbdcdaa768c2ceed","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Common Stock Purchase Agreement.","evidence_excerpt":"BAX entered into a common stock purchase agreement (the “ Common Stock Purchase Agreement ”) with the Lead Investor, pursuant to which the Company may sell and issue, and the Lead Investor is obligated to purchase, up to the greater of (i) 2,977,070 shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"}],"fact_type":"material_agreement"},{"claim_id":"50493393878b9eb0757c7ecf8829e9226896abd2","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into Sponsor Share Forfeiture Agreement.","evidence_excerpt":"Sponsor Share Forfeiture Agreement At Closing, the Sponsor entered into the Sponsor Share Forfeiture Agreement, pursuant to which, upon the terms and subj","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"}],"fact_type":"material_agreement"},{"claim_id":"87d5ed7e937fe65fd253825c8d7dc0dc7b682d33","claim":"CERO THERAPEUTICS HOLDINGS, INC. entered into ELOC Registration Rights Agreement.","evidence_excerpt":"Concurrent with the execution of the Common Stock Purchase Agreement, the Company entered into a registration rights agreement with the Lead Investor (the “ ELOC Registration Rights Agreement ”),","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024017157/0001213900-24-017157-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}